摘要
Abstract
Objective To investigate the effect of bevacizumab combined with the XELOX regimen on the serum levels of tumor markers in patients with advanced colon cancer.Methods A total of 72 pa-tients with advanced colon cancer treated in our hospital from January 2022 to December 2023 were select-ed and randomly divided into an observation group and a control group,with 36 cases in each group.The observation group was treated with the XELOX regimen combined with bevacizumab,while the control group was treated with the XELOX regimen alone.The curative effects,serum levels of tumor markers,quality of life,health status and adverse reactions were compared between the two groups.Results The objective remission rate and the Karnofsky performance status score after treatment in the observation group were higher than those in the control group(P＜0.05),and the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 242(CA242),carbohydrate antigen 724(CA724)and the quality of life score were lower than those in the control group(P＜0.05).There were no statistically significant differences in the incidences of neurotoxicity,gastrointestinal reactions,myelosuppression,leukopenia,alopecia and abnormal liver and kidney functions between the two groups during the treatment(P＞0.05).Conclu-sion Bevacizumab combined with the XELOX regimen in the treatment of advanced colon cancer can en-hance the anti-tumor effect,reduce the levels of CEA,CA242 and CA724,improve the health status and quality of life of patients,and has a higher safety.关键词
晚期结肠癌/贝伐珠单抗/奥沙利铂/卡培他滨/肿瘤标志物Key words
Advanced colon cancer/Bevacizumab/Oxaliplatin/Xeloda/Tumor markers
